OGD Petition
- Vancocin Legal Submission (PDF)
- Vancocin Scientific Submission (PDF)
- Exploratory study in CDAD (PDF)
January 2008 meeting slides and supplemental materials
- ViroPharma slide presentation to OPS/OGD (PDF)
- December 2007 Docket Submission (PDF)
- August 2007 Docket Submission (PDF)
- May 2007 Docket Submission (PDF)
January 2008 letter to OPS (PDF)
July 2008 submission: Comments to Advisory Committee (PDF)
March 2009 submission: Comments to Draft Guidance on BE recommendation for Vancomycin HCL (PDF)
The materials linked from this page contain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Current reports on Form 8-K filed with the SEC on January 8, 2008 and March 18, 2009 as well as in the Sections entitled “Risk Factors” of our Annual Report on Form 10-K for the periods ended December 31, 2008 as filed with the Securities and Exchange Commission.